...
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >EMPAGLIFLOZIN: A NEW TREATMENT OPTION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS
【24h】

EMPAGLIFLOZIN: A NEW TREATMENT OPTION FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS

机译:Empagliflozin:2型糖尿病患者的新治疗选择

获取原文
获取原文并翻译 | 示例
           

摘要

Empagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces hyperglycemia in type 2 diabetes mellitus (T2DM) by decreasing renal glucose reabsorption and promoting urinary glucose excretion. In clinical trials, empagliflozin demonstrated significant improvements in glycemic control, as monotherapy and in combination regimens. In addition, empagliflozin was associated with weight loss and moderate reductions in blood pressure. In the EMPA-REG OUTCOME study, empagliflozin significantly reduced the risk of the composite primary endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Across the trials in general, empagliflozin was well tolerated, with no increased risk of hypoglycemia except when used with an insulin secretagogue or insulin. An increased risk of genital infections and urinary tract infections has been reported, although the association is less clear for urinary tract infections. Overall, empagliflozin appears to be a promising treatment for T2DM.
机译:Empagliflozin是一种口服钠 - 葡萄糖COT转折剂2(SGLT2)抑制剂,通过减少肾葡萄糖重吸收和促进尿葡萄糖排泄,减少2型糖尿病(T2DM)的高血糖症。在临床试验中,Empagliflozin显示出血糖控制的显着改善,作为单药治疗和组合方案。此外,Empagliflozin与体重减轻和血压中的中度减少有关。在EMPA-REG结果研究中,Empagliflozin显着降低了心血管死亡,非致死性心肌梗死和非缺乏中风的复合初级终点的风险。通常,empagliflozin耐受良好的耐受性,除了与胰岛素促胰岛素或胰岛素一起使用时,低血糖风险没有增加。据报道了生殖器感染和泌尿道感染的风险增加,尽管尿路感染不太清楚。总体而言,Empagliflozin似乎是T2DM的有希望的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号